

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**COMMON SPLENDOR INTERNATIONAL
HEALTH INDUSTRY GROUP LIMITED**

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

**(1) COMPLETION OF DISCLOSEABLE TRANSACTION
IN RELATION TO THE ISSUE OF
11% SECURED AND GUARANTEED NOTE IN THE
PRINCIPAL AMOUNT OF HK\$100,000,000 DUE 2018 TO CCBI**

AND

**(2) UPDATE ON THE MAJOR TRANSACTION, FINANCIAL ASSISTANCE
AND CONTINUING CONNECTED TRANSACTION**

COMPLETION OF ISSUE OF 11% SECURED AND GUARANTEED NOTE TO CCBI

The Board is pleased to announce that all the Conditions under the Subscription Agreement have been fulfilled and completion of the issue of the Note to CCBI took place on 21 December 2016.

**UPDATE ON THE MAJOR TRANSACTION, FINANCIAL ASSISTANCE AND
CONTINUING CONNECTED TRANSACTION**

The Board hereby announces that the parties to the New Facility Agreement entered into a Supplemental Agreement on 21 December 2016 to increase the interest rate of the three-year revolving facility under the New Facility Agreement from 10% per annum to 11% per annum.

(1) COMPLETION OF ISSUE OF 11% SECURED AND GUARANTEED NOTE TO CCBI

Reference is made to the announcement of the Company dated 14 December 2016 in relation to the issue of the Note to CCBI pursuant to the Subscription Agreement (the “**Announcement**”). Unless otherwise defined herein, capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Board is pleased to announce that all the Conditions under the Subscription Agreement have been fulfilled and completion of the issue of the Note to CCBI took place on 21 December 2016.

The Note, in the principal amount of HK\$100,000,000, was issued to the Investor on 21 December 2016. The net proceeds from the issue of the Note is estimated to be approximately HK\$99,500,000 and will be used by the Group to fund its working capital and for the development of existing healthcare business of the Group.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, the Investor and its ultimate beneficial owner are independent of the Company and its connected persons (as defined in the Listing Rules).

(2) UPDATE ON THE MAJOR TRANSACTION, FINANCIAL ASSISTANCE AND CONTINUING CONNECTED TRANSACTION

Reference is made to the circular of the Company dated 2 November 2015 in relation to, inter alia, the major and continuing connected transaction relating to the new facility agreement dated 2 October 2015 (the “**New Facility Agreement**”) entered into among the Company as the lender, Champion Dynasty Limited (“**Champion Dynasty**”) as the borrower and Mr. Cheung Wai Kuen (“**Mr. Cheung**”) as the individual guarantee. Pursuant to the New Facility Agreement, the Company agreed to make available to Champion Dynasty a three-year revolving facility of up to HK\$200 million.

The Board hereby announces that after arm’s length negotiations, the parties to the New Facility Agreement entered into a supplemental agreement (the “**Supplemental Agreement**”) on 21 December 2016 to increase the interest rate of the three-year revolving facility under the New Facility Agreement from 10% per annum to 11% per annum. The Directors (including the independent non-executive Directors) consider that the terms of the Supplemental Agreement are better than the terms under the New Facility Agreement, and are fair, reasonable and in the interests of the Company and the Shareholders as a whole.

To the best of the Directors’ knowledge, information and belief, save for Mr. Cheung and his associates, no Directors have a material interest in the Supplemental Agreement. Mr. Cheung has abstained from voting in the relevant resolutions of the Board approving the Supplemental Agreement.

The Company is of the view that the revised interest rate under the Supplemental Agreement is fair and reasonable in the current market circumstances and on normal commercial terms and does not constitute a material change of the terms of the New Facility Agreement. Save as disclosed above, all other terms of the New Facility Agreement shall remain unchanged.

On behalf of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 21 December 2016

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Bai Yinghai as non-executive Directors; and Mr. Mai Yang Guang, Mr. Yau Chi Ming and Mr. Lam Chi Wing as independent non-executive Directors.